Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report

doi:10.12998/wjcc.v10.i34.12703

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2463)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

140

WORD

HTML

961

Figures (1-4)

303

Sum=1432

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

250

Download

748

Sum=998

Dec 6, 2022 (publication date) through May 19, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Dec 6, 2022; 10(34): 12703-12710
Published online Dec 6, 2022. doi: 10.12998/wjcc.v10.i34.12703

Full Size Figure Download Figure

Figure 2 Positron emission tomography/computerized tomography evaluations. A: Positron emission tomography/computerized tomography (PET/CT) showed no abnormal metabolism lesions at diagnosis; B: PET/CT examination showed significantly positive lesions and confirmed refractory/relapse after first-line therapy. The red arrows indicate increased-fluorodeoxyglucose metabolism lesions.

Citation: Li X, Pan XH, Fang Q, Liang Y. Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report. World J Clin Cases 2022; 10(34): 12703-12710
URL: https://www.wjgnet.com/2307-8960/full/v10/i34/12703.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i34.12703